340B Drug Pricing Program
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.
AHA 340B Advocacy Alliance for September 8, 2025.
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
340B Advocacy Alliance Bulletin for September 5, 2025.
340B Advocacy Alliance Bulletin for September 3, 2025.
Reps. Doris Matsui, D-Calif., Dusty Johnson, R-S.D., Debbie Dingell, D-Mich., and Tracey Mann, R-Kan., are circulating a “Dear Colleague” letter asking House members to sign a letter to the Department of Health and Human Services expressing concerns about the recently announced 340B Rebate Model…
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.
AHA comments to HRSA on proposed 340B rebate model program; register for Aug. 28 AHA call to discuss rebate model.
AHA comments on the Health Resources and Services Administration’s notice of the 340B Rebate Model Pilot Program.
The AHA 340B Advocacy Alliance will host a call Aug. 28 at 12:30 p.m. ET to provide insights into the association’s comments to the Health Resources and Services Administration about the agency’s 340B Rebate Model Pilot Program, which will be shared with members next week.